The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.

U.S. President Donald Trumphas signed an executive order demanding a speedy reclassification of marijuana that would ease federal restrictions on research that could lead to new medical marijuana products.

U.S. Rep. Greg Steube says President Donald Trump’s order to reschedule marijuana offers a window for Congress to pass his bill doing just that.

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today applauds the Trump Administration's action to implement the most impactful federal cannabis reform of the past fifty years by rescheduling cannabis as a Schedule III substance under the Controlled Substances Act of 1970.

The Texas Hemp Business Council (THBC) issued the following statement in response to President Donald Trump’s executive order directing the expedited rescheduling of marijuana to Schedule III under the Controlled Substances Act and urging Congress to ensure patient access to full-spectrum,

Every country has a published controlled substance list, but the named substances are only common examples. The list also covers analogs and defined chemical space around these substances, which complicates matters for chemical suppliers, manufacturers ...

As providers are becoming more comfortable with delivering care via telemedicine technologies, many of them are looking to explore services other than low acuity triage consults. One area of patient service opportunity – and particular confusion – is ...

Dr. Clark allegedly bought controlled substances for purposes unrelated to his profession and then kept and dealt the substances from an unregistered location.